Description

Anavex Life Sciences Corp. (Anavex) is a development-stage biopharmaceutical company engaged in the discovery and development of drug targets for the treatment of cancer and diseases of the central nervous system. The ANAVEX portfolio involves sigma receptor compounds (ligands) in the preclinical-stage that target neurodegenerative diseases and cancer. Anavex’s SIGMACEPTOR discovery platform has resulted in the generation of small molecule drug candidates, by making use of sigma receptors, which represent potential targets for therapeutic developments in human diseases, such as Alzheimer’s disease (AD), depression, epilepsy and cancer. The Company’s ANAVEX SIGMACEPTOR-N program involves the discovery and development of drug candidates, targeting neurological diseases, such as AD, epilepsy, depression and pain. Its ANAVEX SIGMACEPTOR-C program involves the discovery and development of original drug candidates targeting cancer.